Smart Innovation
Antimicrobial resistance (AMR)
AMR develops when bacteria, fungi or viruses are exposed to antibiotics, antifungals or antivirals. As a result, the antimicrobials become ineffective and infections may persist. In addition, medical interventions including surgery, chemotherapy and stem cell therapy may become impossible.
AMR is considered the biggest global threat of Health and Food Safety.
AMR Insights
For Researchers and Entrepreneurs who wish to investigate, develop and commercialize novel vaccines, diagnostics and antimicrobials to prevent Antimicrobial resistance, AMR Insights offers selected, global information and data, specific education and extensive networking and partnering opportunities.
AMR Insights is for:
- Researchers at Universities and University Medical Centers
- Researchers at Research Institutes
- R&D professionals in Pharma, Biopharma and Diagnostics companies
- Entrepreneurs in start-up’s and spin off companies
- Innovators, Venture Capitalists.
Latest Topics
-
27 January 2026An overview of global public and philanthropic investments into antibacterial therapeutics (2017–23)
The article analyses global public and philanthropic funding trends for antibacterial therapeutic research and development (R&D) between 2017 and 2023, revealing that current investment levels remain inadequate relative to the urgent need for new antibiotics and related therapies to address rising antimicrobial resistance; it highlights persistent gaps in funding, especially for early-stage discovery and clinical […]
Read more... -
27 January 2026Measuring Infectious Causes and Resistance Outcomes for Burden Estimation (MICROBE)
The MICROBE (Measuring Infectious Causes and Resistance Outcomes for Burden Estimation) tool from the Institute for Health Metrics and Evaluation (IHME) is an interactive data visualization platform that displays global estimates of both fatal and non-fatal health outcomes related to infectious diseases and antimicrobial resistance, by pathogen, region, age and sex. It integrates data from […]
Read more... -
27 January 2026GARDP and Debiopharm Partner to Advance Development of Novel Gonorrhea Drug
GARDP and Swiss biopharmaceutical company Debiopharm have signed a collaboration and license agreement to jointly advance Debio1453, a novel first-in-class antibiotic targeting Neisseria gonorrhoeae, in response to the global surge in multidrug-resistant gonorrhea that now threatens the effectiveness of existing treatments. Under the partnership, Debiopharm will complete the Phase I trial while GARDP leads further […]
Read more...
More news related to Smart innovation
